Principal Financial Group Inc. Acquires New Holdings in iRadimed Corporation $IRMD

Principal Financial Group Inc. bought a new position in iRadimed Corporation (NASDAQ:IRMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,927 shares of the medical equipment provider’s stock, valued at approximately $422,000.

Several other hedge funds have also modified their holdings of IRMD. CWM LLC grew its position in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in iRadimed in the third quarter worth $47,000. Spire Wealth Management acquired a new position in shares of iRadimed during the second quarter worth $60,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of iRadimed by 30.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,056 shares of the medical equipment provider’s stock valued at $123,000 after purchasing an additional 477 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the completion of the sale, the chief executive officer directly owned 2,262,500 shares in the company, valued at $227,720,625. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the transaction, the chief financial officer owned 7,362 shares in the company, valued at $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 50,000 shares of company stock worth $4,859,950. 36.80% of the stock is currently owned by corporate insiders.

iRadimed Trading Down 0.6%

Shares of iRadimed stock opened at $100.86 on Friday. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $107.90. The firm has a market capitalization of $1.28 billion, a PE ratio of 57.63 and a beta of 1.11. The firm’s 50-day moving average price is $98.82 and its 200 day moving average price is $85.10.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed had a return on equity of 23.85% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, sell-side analysts predict that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Monday, February 23rd will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s payout ratio is 38.86%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research raised shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Lake Street Capital restated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.